MedTrace Logo

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT02955615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-03-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.

Conditions

Interventions

DRUG

ILT-101

Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy. SLE background therapy includes ...

DRUG

Placebo

Induction phase followed by weekly administrations of placebo on top of SLE background therapy. SLE background therapy includes ...

Sponsors & Collaborators

  • Iltoo Pharma

    lead INDUSTRY

Principal Investigators

  • David Klatzmann, MD, PhD · Assistance Publique Hôpitaux de Paris (AP-HP)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-18
Primary Completion
2018-08-27
Completion
2019-02-11

Countries

  • Austria
  • Bulgaria
  • France
  • Germany
  • Italy
  • Mauritius
  • Mexico
  • Portugal
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955615 on ClinicalTrials.gov